Biodesix
BDSX----
Q3 FY2026 EarningsQ3 FY26 missed consensus on the top line with revenue of $24.0M vs. $27.5M expected, while GAAP EPS of -$0.75 was in-line with the -$0.75 consensus. Diagnostic Testing revenue grew 16% YoY, but overall growth was hampered by sales execution issues and seasonality. Management revised FY26 revenue guidance downward to $101M–$103M, well below previous expectations, reflecting delayed project execution and slower-than-planned sales team ramp-up.
Financial report interval: 2026.06.30 - 2026.09.30
Overview: Biodesix(BDSX) the Revenue is 24.04 M (+10.44%), Miss estimate;the EBIT is -6.112 M (+13.32%), Miss estimate;the EPS is -0.75 (+35.34%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.02B10.44%
0.03B26.27%
-0.00B15.83%
EBITMiss expectations
-0.01B13.32%
-0.01B17.01%
-0.00B3.69%
EPSMiss expectations
-0.7535.34%
-0.748635.47%
-0.00140.13%
Upcoming earnings report - Annual FY2026
Available dateFeb 26, 2027
Estimate Revenue$105.39 M
Estimate EBIT-$22.31 M
Estimate EPS-$2.8371
Revenue
ActualEstimateUnit: USD
Quarterly
EBIT
ActualEstimateUnit: USD
Quarterly
Net income
ActualEstimateUnit: USD
Quarterly
EPS
ActualEstimateUnit: USD
Quarterly